Know Cancer

or
forgot password

Serum Carbonic Anhydrase 9 (CA9) Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer : a Pilot Study


N/A
18 Years
N/A
Open (Enrolling)
Both
Metastatic Kidney Cancer, Metastatic Renal Cell Carcinoma

Thank you

Trial Information

Serum Carbonic Anhydrase 9 (CA9) Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer : a Pilot Study


We propose a pilot study of CA9 serum in patients with adenocarcinoma metastatic cell
treated by conventional immunotherapy and / or targeted therapy. This pilot study aims to
test the CA9 serum marker of response to medical treatment


Inclusion Criteria:



- Conventional renal cell cancer with a pathological diagnosis

- Metastatic disease

- Consent form signed

- social security regimen affiliated

Exclusion Criteria:

- Other cancer treated

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

serum protein CA9 and mRNA CA9 level under medical treatment

Outcome Time Frame:

before treatment, at 1, 3, 6, 9 and 12 months

Safety Issue:

No

Principal Investigator

Jacques TOSTAIN, MD-PhD

Investigator Role:

Study Director

Investigator Affiliation:

CHU de Saint-Etienne

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

0808071

NCT ID:

NCT00942058

Start Date:

June 2009

Completion Date:

November 2013

Related Keywords:

  • Metastatic Kidney Cancer
  • Metastatic Renal Cell Carcinoma
  • biological markers
  • CA9 protein
  • metastatic conventional renal cell cancer
  • kidney cancer
  • Carcinoma
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Name

Location